OKYO Pharma Limited
EMMLF · OTC
3/31/2025 | 10/1/2024 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1,561 | – | $987 | $827 |
| Short-Term Investments | $0 | – | $0 | $0 |
| Receivables | $1,889 | – | $1,516 | $581 |
| Inventory | $0 | – | $0 | $0 |
| Other Curr. Assets | $225 | – | $324 | $130 |
| Total Curr. Assets | $3,675 | – | $2,827 | $1,538 |
| Property Plant & Equip (Net) | $2 | – | $2 | $3 |
| Goodwill | $0 | – | $0 | $0 |
| Intangibles | $0 | – | $0 | $0 |
| Long-Term Investments | $0 | – | $0 | $0 |
| Tax Assets | $0 | – | $0 | $0 |
| Other NC Assets | $0 | – | $0 | $0 |
| Total NC Assets | $2 | – | $2 | $3 |
| Other Assets | $0 | – | $0 | $0 |
| Total Assets | $3,677 | – | $2,829 | $1,541 |
| Liabilities | – | – | – | – |
| Payables | $7,900 | – | $9,607 | $6,128 |
| Short-Term Debt | $0 | – | $2 | $0 |
| Tax Payable | $0 | – | $0 | $0 |
| Deferred Revenue | $0 | – | $0 | $0 |
| Other Curr. Liab. | $1,327 | – | $446 | $1,293 |
| Total Curr. Liab. | $9,227 | – | $10,054 | $7,421 |
| LT Debt | $0 | – | $0 | $0 |
| Deferred Rev, NC | $0 | – | $0 | $0 |
| Deferred Tax Liab, NC | $0 | – | $0 | $0 |
| Other NC Liab. | $0 | – | $0 | $0 |
| Total NC Liab. | $0 | – | $0 | $0 |
| Other Liabilities | $0 | – | $0 | $0 |
| Cap. Leases | $0 | – | $0 | $0 |
| Total Liabilities | $9,227 | – | $10,054 | $7,421 |
| Equity | – | – | – | – |
| Pref Stock | $0 | – | $0 | $0 |
| Common Stock | $0 | – | $0 | $143,113 |
| Retained Earnings | -$143,025 | – | -$145,202 | -$142,523 |
| AOCI | -$11,470 | – | -$6,073 | -$11,311 |
| Other Equity | $148,946 | – | $144,049 | $4,842 |
| Total Equity | -$5,550 | – | -$7,226 | -$5,880 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | – | $0 | $0 |
| Total Liab. & Tot. Equity | $3,677 | – | $2,829 | $1,541 |
| Net Debt | -$1,561 | $0 | -$985 | -$827 |